Table 1. Baseline clinical and demographic characterization in the overall population and naïve vs non-naïve patients.
| Characteristics | Overall population, n=57 eyes | Naïvea, n=34 eyes | Non-naïvea, n=19 eyes | P |
| Age (mean±SD) | 67.6±8.7 | 67.1±8.2 | 68.6±9.5 | 0.568 |
| Gender | 0.095 | |||
| Female | 22 (46.8) | 13 (38.2) | 12 (63.2) | |
| Male | 25 (53.2) | 21 (61.8) | 7 (36.8) | |
| Lens | 0.570 | |||
| Phakic | 29 (61.7) | 21 (61.8) | 10 (52.6) | |
| Pseudophakic | 18 (38.3) | 13 (38.2) | 9 (47.4) | |
| Cataract | 0.673 | |||
| Cataract with no impact on patients' vision | 2 (3.5) | 1 (2.9) | 1 (5.3) | |
| Cataract clinically relevant with impact on patient vision | 6 (10.5) | 3 (8.8) | 3 (15.8) | |
| Diabetes characterization | ||||
| Duration of diabetes mellitus (y) | 16.9 (9.0) | |||
| Diabetic patient treated with insulin | ||||
| No | 36 (76.6) | |||
| Yes | 11 (23.4) | |||
| Duration of DME (mo) | 10.6 (12.6) | 6.2 (10.2) | 20.2 (12.1) | 0.001b |
| Previous anti-VEGF injections | ||||
| Naïve patients | 34 (64.2) | 34 (100) | ||
| Non-naïve patients | 19 (35.8) | 19 (100) | ||
| BCVA (ETDRS letters) at baseline (mean±SD) | 50.56±16.50 | 51.8±15.8 | 49.8±18.6 | 0.684 |
| IOP (mm Hg) at baseline (mean±SD) | 17.28±3.60 | 17.2±2.6 | 17.2±5.2 | 0.456 |
| CMT at baseline (mean±SD) | 501.80±141.82 | 507.6±117.8 | 488.3±175.3 | 0.250 |
| Presence of neurosensorial detachment | 0.334 | |||
| No | 44 (77.2) | 24 (70.6) | 16 (84.2) | |
| Yes | 13 (22.8) | 10 (29.4) | 3 (15.8) |
DME: Diabetic macular edema; BCVA: Best corrected visual acuity; CMT: Central macular thickness; ETDRS: Early Treatment Diabetic Retinopathy Study; IOP: Intraocular pressure; SD: Standard deviation; VEGF: Vascular endothelial growth factor. aFour patients were excluded from the subanalysis due to uncertain number of previous anti-VEGF injections. bStatistically significant result.